{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:53:56Z","timestamp":1770994436410,"version":"3.50.1"},"reference-count":14,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In this study 19 patients were preoperatively treated with octreotide for 1\u201317 months (mean, 5 months), with doses from 150\u20131500 \u03bcg daily, and those patients were matched to 19 untreated patients with comparable tumor classification and preoperative serum GH concentrations. Octreotide was started at 300 \u03bcg daily by sc injections or continuous sc infusion using a pump in increasing doses, depending on the responses of the serum GH and insulin-like growth factor I (IGF-I) concentrations. During pretreatment, seven patients achieved a serum GH concentration below 5 mU\/L, whereas six patients normalized their serum IGF-I.<\/jats:p>\n               <jats:p>Postoperatively, a serum GH concentration below 5 mU\/L was achieved in 15 pretreated and 14 untreated patients, a normal serum IGF-I level (&amp;lt;2 sd) was achieved in 10 pretreated and 15 untreated patients, and normal serum GH suppression during GTT was reached in 12 treated and 14 control patients. No differences were found in complication rate or incidence of hypopituitarism caused by surgery.<\/jats:p>\n               <jats:p>Adjuvant therapy was required in 7 treated and 5 untreated patients. At follow-up examination, 5.7 and 4 yr postoperatively, 10 pretreated and 12 control patients could be considered cured by surgery only, according to our criteria for remission (serum GH, &amp;lt;5 mU\/L; normal GH suppression and normal serum IGF-\u0399). In summary, we found no difference in direct postoperative and follow-up results of transsphenoidal surgery between pretreated patients and untreated patients. This finding is in discordance with other studies, which have claimed a beneficial effect of octreotide pretreatment.<\/jats:p>","DOI":"10.1210\/jcem.84.10.6027","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:03:58Z","timestamp":1389200638000},"page":"3551-3555","source":"Crossref","is-referenced-by-count":69,"title":["Direct Postoperative and Follow-Up Results of Transsphenoidal Surgery in 19 Acromegalic Patients Pretreated with Octreotide Compared to Those in Untreated Matched Controls"],"prefix":"10.1210","volume":"84","author":[{"given":"N. R.","family":"Biermasz","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Leiden University Medical Center, 2333AA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"van Dulken","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Leiden University Medical Center, 2333AA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Roelfsema","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Leiden University Medical Center, 2333AA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071613434297000_R1","first-page":"617","article-title":"Factors determining long term outcome of surgery in acromegaly","volume":"87","author":"Osman","year":"1994","journal-title":"Q J Med."},{"key":"2020071613434297000_R2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2265.1995.tb02913.x","article-title":"The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly","volume":"43","author":"Jenkins","year":"1995","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2020071613434297000_R3","first-page":"293","article-title":"An audit of the treatment of acromegaly","volume":"86","author":"Bates","year":"1993","journal-title":"Q J Med."},{"key":"2020071613434297000_R4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0002-9343(94)90327-1","article-title":"Consensus statement: benefits vs risks of medical therapy for acromegaly","volume":"97","year":"1994","journal-title":"Am J Med."},{"key":"2020071613434297000_R5"},{"key":"2020071613434297000_R6","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jcem.82.10.4283","article-title":"Effect of octreotide pretreatment on surgical outcome in acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071613434297000_R7"},{"key":"2020071613434297000_R8","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jcem-67-5-1040","article-title":"Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201\u2013995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate","volume":"76","author":"Barkan","year":"1988","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071613434297000_R9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3171\/jns.1994.81.1.0010","article-title":"Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201\u2013995 before transsphenoidal surgery","volume":"81","author":"Lucas-Morante","year":"1994","journal-title":"J Neurosurg."},{"key":"2020071613434297000_R10","first-page":"1416","article-title":"Preoperative octreotide treatment of growth-hormone secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy","volume":"79","author":"Plockinger","year":"1994","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071613434297000_R11"},{"key":"2020071613434297000_R12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1530\/acta.0.1140249","article-title":"Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations","volume":"114","author":"Spinas","year":"1987","journal-title":"Acta Endocrinol (Copenh)."},{"key":"2020071613434297000_R13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2265.1998.00581.x","article-title":"The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma","volume":"49","author":"Lissett","year":"1998","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2020071613434297000_R14","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jcem.83.10.5111","article-title":"Transsphenoidal microsurgery for growth hormone secreting pituitary adenomas: initial outcome and long-term results","volume":"83","author":"Abosch","year":"1998","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/84\/10\/3551\/9059884\/jcem3551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/84\/10\/3551\/9059884\/jcem3551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:30:22Z","timestamp":1594945822000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/84\/10\/3551\/2660552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10,1]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.84.10.6027","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10,1]]}}}